Time was the most critical criterion; only 14% of the patients were admitted in due time. However, this percentage would probably increase if alteplase were approved, so we also estimated treatment effect assuming the ideal-all patients admitted in due time. In this case 539 patients (45%) would have been eligible (figure). Of these patients, 119 died and 150 had full recovery, leaving 270 patients who survived but did not achieve full recovery who could have benefited from treatment. An estimated 48 patients (150 × 0.32 = 48 (1 to 105)), or 4% (0.1% to 8%) of the stroke population, would have benefited from treatment.
because evaluation of patient and paraclinical data requires a specialist setting, treatment with alteplase will need large investments and reorganisation of the care for stroke patients. Before it is decided to offer this expensive, potentially harmful, and possibly only marginally effective treatment we suggest that another, much larger, European trial is needed to test the results of the US trial.
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Patients, methods, and results
One hundred and three pairs of nasopharyngeal secretions were obtained from 98 children under 2 years of age presenting with respiratory symptoms (five children presented twice). The first specimen was sent for direct immunofluorescence testing at the Regional Clinical Virology Laboratory, City Hospital, Edinburgh (accredited by Clinical Pathology Accreditation (UK)) using the Imagen respiratory syncytial virus reagent (Dako, Ely, United Kingdom). The second specimen (taken immediately afterwards but often smaller in volume) was tested by staff of the accident and emergency department using an enzyme immunoassay (Abbott TestPack RSV, Abbott Laboratories, North Chicago, IL).
This protocol was adopted to avoid compromising the results of direct immunofluorescence testing (our routine method) while the pilot study was in progress. Staff training and near patient testing were carried out in accordance with published guidelines.
5 Patients with positive results by the near patient test were isolated or put with others with positive results; those with negative results were also isolated if possible while awaiting further results.
The 
Comment
The high specificity (97%) of the enzyme immunoassay in this pilot confirmed results from a laboratory based study.
3 The comparatively low sensitivity (79%), although comparable with the sensitivity in another study, 3 is partially explicable by our using a second, often smaller, specimen for the test. Our results suggest that a positive result of a near patient test is trustworthy and does not require laboratory confirmation (allowing considerable savings in both time and cost) but a negative result needs further investigation. Only one specimen per patient should routinely be required, but this should be treated aseptically to allow for possible laboratory referral.
Near patient testing for respiratory syncytial virus is a viable option for paediatric accident and emergency with important potential benefits.
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Conflict of interest: None declared. Infection with hepatitis C and hepatitis B viruses is common among injecting drug users. [1] [2] [3] [4] In a sample of blood donors only 0.01% were positive for antibodies to hepatitis C virus, 5 whereas 59% of injecting drug users in East Anglia were positive, with 22% also positive for hepatitis B virus.
2 Rhodes et al reported that about half (58% in 1992 and 50% in 1993) of those whose salivary specimens contained antibodies to hepatitis B virus were unaware of their infection. 4 Although drug users are generally aware of the risks of infection, their awareness of their own status is uncertain. We tested opiate addicts receiving methadone maintenance treatment for markers of hepatitis B and hepatitis C infection and compared the results with their beliefs about their viral status.
Subjects, methods, and results
We collected data on 106 injecting opiate addicts attending a methadone maintenance clinic in London. Sufficient blood was obtained for 90 hepatitis C virus tests and for 84 hepatitis B virus tests (when blood was insufficient, priority was given to hepatitis C). We present data for the 90 addicts from whom blood was obtained.
The participants' mean age was 36 years (range 21-54), and 69 were men. They had attended the clinic for an average of 2.4 years and received a mean methadone dose of 72 mg (range 15-150 mg). Their mean age at first opiate injection was 21, and the mean duration of injecting was 15 years. Fifty nine had used a syringe after someone else, and 68 had shared injecting paraphernalia.
Seventy seven were positive for hepatitis C virus, and 46 were positive for hepatitis B virus. Of the 79 who reported having previously been tested for hepatitis C virus, 58 thought they were positive, 16 thought they were negative (of whom half were wrong), and five were uncertain. Of the 70 addicts previously tested for hepatitis C virus whom we found to be positive, 12 did not know or were wrong about their status (see table) . Of the 41 previously tested for hepatitis B virus whom we found to be positive, 16 thought themselves to be negative.
Of the 11 addicts never previously tested for hepatitis C virus, four were correct in their self assessment (one positive, three negative), four incorrectly thought they were negative, and three did not know. Of the 22 addicts not previously tested for hepatitis B virus, six were correct in their self assessment (all negative), while three mistakenly believed they were positive and one negative, and 12 could not report their viral status (five positive, seven negative). 
